Effects of calcium antagonists on the risks of coronary heart disease, cancer and bleeding

Journal of Human Hypertension

Volumn 11, Issue 6, 1997, Pages 331-342

  Chalmers, John ^a  

^a ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

Calcium antagonists; Observational studies; Randomised controlled trials; Risks of bleeding; Risks of cancer; Risks of coronary disease

Indexed keywords

CALCIUM ANTAGONIST;

ANGINA PECTORIS; BLEEDING; CANCER; CANCER RISK; CHINA; CORONARY RISK; DRUG SAFETY; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; JAPAN; METHODOLOGY; REVIEW; STROKE;

EID: 0030878698     PISSN: 09509240     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.jhh.1000467     Document Type: Review

References (81)

1. Collins R, Peto R, Gray R, Parish S. Large-scale randomized evidence: trials and overviews. In: Weatherall D, Ledingham J, Warrell D (eds). Oxford Textbook of Medicine. Third Edition. Oxford: Oxford University Press, 1996, pp 21-32.
2. Collins R, Gray R, Godwin J, Peto R. Avoidance of large biases and large random errors in the assessment of moderate treatment effects: the need for systematic overviews. Stat Med 1987; 6: 245-250.
3. Bigger J et al. Effect of digitalis treatment on survival after acute myocardial infarction. Am J Cardiol 1985; 55: 623-630.
4. Yusuf S et al. Which heart failure patients benefit the most from long-term digoxin therapy. Circulation 1996; 94: I-23.
5. Yusuf S, Furberg C, Wittes J, Bailey K. Digitalis - a new controversy regarding an old drug: the pitfalls of inappropriate methods. Circulation 1986; 73: 14-18.
6. Grady D et al. Hormone replacement therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992; 117: 1016-1037.
7. Collins R et al. Blood pressure, stroke, and coronary heart disease. Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990; 335: 827-839.
8. Collins R, MacMahon S, Blood pressure, antihypertensive drug treatment and the risks of stroke and of coronary heart disease. Br Med Bull 1994; 50: 272-298.
9. Antiplatelet Trialists Collaboration. Secondary prevention of vascular disease by prolonged antiplatelet treatment. Br Med J 1988; 296: 320-331.
10. Antiplatelet Trialists Collaboration. Collaborative overview of randomised trials of antiplatelet therapy. Part I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994; 308: 71-72.
11. Thumer H, Lund-Larsen P, Tverdal A. Is blood pressure treatment as effective in a population setting as in controlled trials? Results from a prospective study. J Hypertens 1994; 2: 481-490.
12. Paganini-Hill A, Chao A, Ross R, Henderson B. Aspirin use and chronic diseases: a cohort study of the elderly. Br Med J 1990; 300: 116-118.
13. Israili Z, Hall W. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology. Ann Intern Med 1992; 117: 234-242.
14. MacMahon S et al. Blood pressure, stroke, and coronary heart disease. Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335: 765-774.
15. Flack J et al for the Multiple Risk Factor Intervention Trial Research Group. Blood pressure and mortality among men with prior myocardial infarction. Circulation 1995; 92: 2437-2445.
16. Rodgers A et al on behalf of the UKTIA Collaborative Group. Blood pressure and risk of stroke in patients with cerebrovascular disease. Br Med J 1996; 313: 147.
17. Yusuf S et al. Beta-blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1985; 27: 335-371.
18. Lonn E et al. Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation 1994; 90: 2056-2069.
19. Furberg C, Psaty B, Meyer J. Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. Circulation 1995; 92: 1326-1331.
20. Furberg C, Psaty B. Corrections to the nifedipine metaanalysis. Circulation 1996; 93: 1475-1476.
21. Neaton JD et al. Treatment of Mild Hypertension Study. Final results. J Am Coll Cardiol 1993; 270: 713-724.
22. Materson B. Department of Veteran Affairs single drug therapy of hypertension: final results. Am J Hypertens 1993; 8: 189-192.
23. The GLANT Study Group. A 12-month comparison of ACE-inhibitor and Ca-antagonist therapy in mild to moderate essential hypertension - The GLANT Study. Hypertens Res 1995; 18: 235-244.
24. Borhani N et al. Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS). A randomized controlled trial. JAMA 1996; 276: 785-791.
25. Gong L, Zhang W, Zhu Y, Zhu J. 11 collaborating centres in the Shanghai area Kong D et al. Shanghai trial of nifedipine in the elderly (STONE). J Hypertens 1996; 14: 1237-1245.
26. The Danish Study Group on Verapamil in Myocardial Infarction. Effect of verapamil on mortality and major events after acute myocardial infarction (The Danish Verapamil Infarction Trial-II-DAVIT II). Am J Cardiol 1990; 66: 779-785.
27. Wilcox R et al. Trial of early nifedipine in acute myocardial infarction: the TRENT study. Br Med J 1986; 293: 1204-1208.
28. Held PH, Yusuf S, Furberg CD. Calcium channel blockers in acute myocardial infarction and unstable angina: an overview. Br Med J 1989; 299: 1187-1192.
29. Yusuf S, Held P, Furberg C. Update of effects of calcium antagonists in myocardial infarction or angina in light of the Second Danish Verapamil Trial (DAVIT-II) and other recent studies. Am J Cardiol 1991; 67: 1295-1297.
30. Yusuf S. Verapamil following uncomplicated myocardial infarction: promising, but not proven. Am J Cardiol 1996; 77: 421-422.
31. Rengo F et al. and the CRIS Investigators. A controlled trial of verapamil in patients after acute myocardial infarction. Results of the Calcium Antagonist Reinfarction Italian Study-CRIS. Am J Cardiol 1995; 77: 365-369.
32. Glasser S et al. Exposing patients with chronic, stable, exertional angina to placebo periods in drug trials. JAMA 1991; 265: 1550-1554.
33. Dargie H, Ford I, Fox K, on behalf of the TIBET study group. Total Ischaemic Burden European Trial (TIBET). Effects of ischaemia and treatment with atenolol, nifedipine SR and their combination on outcome in patients with chronic stable angina. Eur Heart J 1996; 17: 104-112.
34. Rehnqvist N et al. Effects of metoprolol vs verapamil in patients with stable angina pectoris. Eur Heart J 1996; 17: 76-81.
35. Cohn J, Ziesche S, Loss L, Anderson G, and the V-HeFT Study Group. Effect of felodipine on short-term exercise and neurohormone and long-term mortality in heart failure: results of V-HeFT VIII. Circulation 1995; 92: I-143.
36. Packer M et al. for the Prospective Randomized Amlodipine Survival Evaluation Study Group. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med 1996; 335: 1107-1114.
37. Littler W, Sheridan D, on behalf of the UK Study Group. Placebo controlled trial of felodipine in patients with mild to moderate heart failure. Br Heart J 1995; 73: 428-433.
38. Psaty B et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 1995; 274: 620-625.
39. Jick H, Derby L, Gurewich V, Vasllakis C. The risk of myocardial infarction in persons with uncomplicated essential hypertension associated with antihypertensive drug treatment. Pharmacotherapy 1996; 16: 321-326.
40. Aursnes I, Litleskare I, Froyland H, Abdelnoor M. Association between various drugs used for hypertension and risk of acute myocardial infarction. Blood Pressure 1995; 4: 157-163.
41. Alderman M, Cohen H, Roque R, Madhavan S. Longand short-acting calcium antagonists differ with regard to cardiovascular outcomes in hypertensive patients. Lancet 1997; 349: 594-598.
42. Mancia G, Van Zwieten P. How safe are calcium antagonists in hypertension and coronary heart disease? J Hypertens 1996; 14: 13-17.
43. Pahor M. Long-term survival and use of antihypertensive medications in older persons. J Am Geriatr Soc 1995; 43: 1-7.
44. Koenig W, Lowel H, Lewis M, Hormann A. Long-term survival after myocardial infarction: relationship with thrombolysis and discharge medication. Results of the Augsburg Myocardial Infarction Follow-up Study 1985 to 1993. Eur Heart J 1996; 17: 1199-1206.
45. Braun S et al, on behalf of the Bezafibrate Infarction Prevention Study Participants. Calcium antagonists and mortality in patients with coronary artery disease: a cohort study of 11,575 patients. J Am Coll Cardiol 1996; 28: 7-11.
46. Abascal V et al. Calcium channel blocker use is not associated with increased mortality. Circulation 1996; 94: I-578.
47. Hamet P. Cancer and hypertension - an unresolved issue. Hypertension 1996; 28: 321-324.
48. Correale P et al. Verapamil upregulates sensitivity of human colon and breast cancer cells to LAK-cytotoxicity in vitro. Eur J Cancer 1991; 27: 1393-1395.
49. Pahor M et al. Do calcium channel blockers increase the risk of cancer? Am J Hypertens 1996; 9: 695-699.
50. Pahor M et al. Calcium-channel blockade and incidence of cancer in aged populations. Lancet 1996; 348: 493-497.
51. Connor J et al. Calcium channel antagonists delay regression of androgen-dependent tissues and suppress gene activity associated with cell death. Prostate 1988; 13: 119-130.
52. 2+ antagonists inhibit DNA fragmentation and toxic cell death induced by acetaminophen. FASEB J 1993; 7: 453-463.
53. deBlois D, Tea B, Dam T, Hamet P. Increased smooth muscle cell apoptosis during regression of vascular hypertrophy in the aorta of spontaneously hypertensive rats. Hypertension 1997; 29 (No. 1 Part 2): 340-349.
54. Ekbom A, Adama H. Kalciumantagonister och cancer - en oversikt. Information Lakemedelsverket 1996; 7: 3-5.
55. Hardell L, Fredrikson M, Axelson O. Case control study on colon cancer regarding previous diseases and drug intake. Int J Oncol 1996; 8: 439-444.
56. Pahor M et al. Risk of gastrointestinal haemorrhage with calcium antagonists in hypertensive persons over 67 years old. Lancet 1996; 347: 1061-1065.
57. Wagenknecht L et al. Surgical bleeding: unexpected effect of a calcium antagonist. Br Med J 1995; 310: 776-777.
58. Pilotto A et al. Antagonism to calcium antagonists. Lancet 1996; 347: 1761-1762.
59. Grodecki-De Franco P et al. Calcium antagonist use and perioperative bleeding complications: an analysis of 5,157 patients. Circulation 1996; 94: I-476.
60. Hynynen M, Kuitunen A, Salmenpera M. Surgical bleeding and calcium antagonists [letter; comment]. Br Med J 1996; 312: 313.
61. The Danish Study Group on Verapamil in Myocardial Infarction. Verapamil in acute myocardial infarction. Eur Heart J 1984; 5: 516-528.
62. The Israeli SPRINT Study Group. Secondary prevention reinfarction Israeli nifedipine trial (SPRINT). A randomized intervention trial of nifedipine in patients with acute myocardial infarction. Eur Heart J 1988; 9: 354-364.
63. Multicenter Diltiazem Post-infarction Trial Research Group. The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med 1988; 319: 385-392.
64. Psaty BM, Sevick MA. Antagonism to calcium antagonists. Lancet 1996; 347: 1761.
65. Robinson M, Teasdale G. Calcium antagonists in the management of subarachnoid haemorrhage. Cerebrovascular and Brain Metabolism Reviews. Raven Press Ltd: New York, 1990, pp 205-226.
66. Pickard JD et al. Effect of oral nimodipine on cerebral infarction and outcome after subarachnoid haemorrhage: British aneurysm nimodipine trial. Br Med J 1989; 298: 636-42.
67. Mohr JP et al. Meta-analysis of oral nimodipine trials in acute ischemic stroke. Cerebrovasc Dis 1994; 4: 197-203.
68. Kaste M et al. A randomized, double-blind, placebo-controlled trial of nimodipine in acute ischemic hemispheric stroke. Stroke 1994; 25: 1348-1353.
69. Takagawa Y, Shimamoto K, Masuda A, Iimura O. Survey of current drug therapy for elderly hypertension. Therapeut Res 1995; 16: 3822-3826.
70. Murros K, Furberg C. Calcium antagonists and extrapyramidal symptoms. Circulation 1996; 94: I-579.
71. Brown M. Calcium-channel blockers and cancer. Lancet 1996; 348: 1166.
72. Boston Collaborative Drug Surveillance Program. Reserpine and breast cancer. Lancet 1974; 2: 669-671.
73. Armstrong B, Stevens N, Doll R. Retrospective study of the association between use of Rauwolfia derivatives and breast cancer. Lancet 1974; 2: 672-674.
74. Heinonen O, Shapiro S, Tuominen L, Turunen M. Reserpine use in relation to breast cancer. Lancet 1974; 2: 675-677.
75. Horwitz R, Feinstein A. Exclusion bias and the false relationship of reserpine and breast cancer. Arch Intern Med 1985; 145: 1873-1875.
76. MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. Br Med J 1992; 304: 405-412.
77. SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 372: 685-691.
78. Walker A, Stampfer M. Observational studies of drug safety. Lancet 1996; 348: 489.
79. Buring J, Glynn R, Hennekens C. Calcium channel blockers and myocardial infarction. A hypothesis formulated but not yet tested. JAMA 1995; 274: 654-655.
80. Easterbrook P, Berlin J, Gopalan R, Matthews D. Publication bias in clinical research. Lancet 1991; 337: 867-872.
81. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. J Am Coll Cardiol 1995; 273: 1450-1456.